Patents Assigned to TAKEDA VACCINES, INC.
-
Patent number: 11464815Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.Type: GrantFiled: March 7, 2019Date of Patent: October 11, 2022Assignee: Takeda Vaccines, Inc.Inventor: Derek Wallace
-
Patent number: 11426461Abstract: The invention relates to a method for preventing dengue disease and hepatitis A in a subject or subject population by simultaneously administering a unit dose of a dengue vaccine composition and a hepatitis A vaccine on the same day. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.Type: GrantFiled: March 4, 2020Date of Patent: August 30, 2022Assignee: Takeda Vaccines, Inc.Inventor: Derek Wallace
-
Publication number: 20220226401Abstract: The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.Type: ApplicationFiled: September 5, 2019Publication date: July 21, 2022Applicant: Takeda Vaccines, Inc.Inventors: Derek WALLACE, Inge LEFEVRE
-
Publication number: 20220211836Abstract: The present invention relates to a liquid inactivated virus composition comprising: an inactivated whole Zika virus, at least one pharmaceutically acceptable buffer with a concentration of at least about 6.5 mM, and optionally a polyol, wherein said at least one pharmaceutically acceptable buffer does not comprise phosphate ions and vaccines derived therefrom.Type: ApplicationFiled: April 8, 2020Publication date: July 7, 2022Applicant: Takeda Vaccines, Inc.Inventors: Michael JOHNSON, Sushma KOMMAREDDY
-
Patent number: 11286282Abstract: The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of, and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample.Type: GrantFiled: October 24, 2019Date of Patent: March 29, 2022Assignee: Takeda Vaccines, Inc.Inventor: Joel R. Haynes
-
Publication number: 20220062375Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: ApplicationFiled: September 17, 2021Publication date: March 3, 2022Applicants: TAKEDA VACCINES, INC., THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENTInventors: Dan T. STINCHCOMB, Claire KINNEY, Richard M. KINNEY, Jill A. LIVENGOOD
-
Patent number: 11197923Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.Type: GrantFiled: November 22, 2019Date of Patent: December 14, 2021Assignee: Takeda Vaccines, Inc.Inventors: Dan Stinchcomb, Jorge E. Osorio, O'Neil Wiggan
-
Patent number: 11091519Abstract: Methods of purifying virus-like particles (VLPs) that are substantially free of process contaminants and infectious agents. The methods incorporate, for example, low-pH treatment during harvest and/or inactivation by a solvent and/or detergent during VLP capture.Type: GrantFiled: November 27, 2018Date of Patent: August 17, 2021Assignee: Takeda Vaccines, Inc.Inventor: Ross Taylor
-
Patent number: 11040097Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.Type: GrantFiled: May 8, 2020Date of Patent: June 22, 2021Assignee: Takeda Vaccines, Inc.Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William Tino
-
Patent number: 11007261Abstract: Embodiments herein concern compositions, methods, and uses for inducing an immune response to all four dengue virus serotypes in a child or young adult from about 1 year to about 20 years of age. Some embodiments concern compositions that can include dengue virus chimeras that, either alone or in combination with other constructs, can be used in vaccine compositions against all four dengue virus serotypes. Compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) virus and/or dengue-4 (DEN-4) virus, at various concentrations or ratios to improve protection from infection in children and young adults. In certain embodiments, viruses of the formulations are limited to dengue virus serotypes. Other embodiments concern methods of administering immunogenic compositions against dengue virus that can include chimeric dengue constructs and live, attenuated dengue viruses using single, dual or other regimens.Type: GrantFiled: April 13, 2017Date of Patent: May 18, 2021Assignee: TAKEDA VACCINES, INC.Inventors: Derek Wallace, John Boslego
-
Patent number: 10920288Abstract: The present invention relates to methods and kits for detecting in a sample the presence of a virus particle or a virus-like particle that has reverse transcriptase activity and methods for preparing a retroviral contaminant-free substance. An aspect of the present invention is a method for detecting the presence of a virus particle in a sample of a Virus-like Particle (VLP) drug substance comprising a step of performing PCR-based reverse transcriptase (PBRT) on a sample of the VLP drug substance that has been treated with a protease.Type: GrantFiled: January 15, 2016Date of Patent: February 16, 2021Assignee: Takeda Vaccines, Inc.Inventors: Joel R. Haynes, Evelyn Benson
-
Patent number: 10898565Abstract: Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions.Type: GrantFiled: June 1, 2018Date of Patent: January 26, 2021Assignees: Takeda Vaccines, Inc., The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Jill A. Livengood, Claire Kinney, Timothy D. Powell, Dan T. Stinchcomb, Jorge Osorio
-
Patent number: 10835597Abstract: Embodiments herein relate to compositions and methods for stabilizing Flaviviruses. In certain embodiments, compositions and methods disclosed herein concern stabilizing live, attenuated or unattenuated (e.g. live whole) flaviviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated or unattenuated flaviviruses. Other embodiments relate to improved formulations for prolonging stabilization of live attenuated or unattenuated Flaviviruses during manufacturing, storage, accelerated storage and transport. Yet other embodiments relate to uses of compositions disclosed herein in kits for transportable applications and methods.Type: GrantFiled: August 3, 2017Date of Patent: November 17, 2020Assignee: TAKEDA VACCINES, INC.Inventors: Jill Ann Livengood, Linda Marie Strange, Steven Michael Erb
-
Patent number: 10806781Abstract: Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.Type: GrantFiled: October 12, 2018Date of Patent: October 20, 2020Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jill A. Livengood, Laszlo Varga
-
Patent number: 10806782Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.Type: GrantFiled: November 6, 2015Date of Patent: October 20, 2020Assignee: Takeda Vaccines, Inc.Inventors: Subash Chandra Das, Joseph David Santangelo, Dan Thomas Stinchcomb, Jorge E. Osorio
-
Patent number: 10792353Abstract: Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.Type: GrantFiled: December 7, 2018Date of Patent: October 6, 2020Assignee: Takeda Vaccines, Inc.Inventors: Thomas S. Vedvick, Bryan Steadman, Charles Richardson, Thomas R. Foubert, Charles R. Petrie
-
Patent number: 10688174Abstract: The present invention relates to vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to methods of conferring protective immunity to Norovirus infections in a human subject.Type: GrantFiled: June 3, 2019Date of Patent: June 23, 2020Assignee: Takeda Vaccines, Inc.Inventors: Charles Richardson, Thomas S. Vedvick, Thomas R. Foubert, William Tino
-
Patent number: 10675341Abstract: The present invention relates to single dose parental vaccine compositions comprising mixtures of monovalent Norovirus virus-like particles. Methods of conferring protective immunity against Norovirus infections in a human subject by administering such compositions are also disclosed.Type: GrantFiled: December 8, 2017Date of Patent: June 9, 2020Assignee: Takeda Vaccines, Inc.Inventors: Charles Richardson, Thomas R. Foubert
-
Patent number: 10632184Abstract: Embodiments herein relate to compositions and methods for stabilizing live alphaviruses. Other embodiments relate to compositions and methods for reducing degradation of live, attenuated alphaviruses. Certain embodiments relate to providing a stabilizing composition while reducing immune reaction in a subject to excipients that stabilize the live alphaviruses by providing improved formulations. Yet other embodiments relate to uses of compositions disclosed herein in kits for portable applications and methods wherein the compositions reduce degradation of the live alphaviruses.Type: GrantFiled: March 27, 2017Date of Patent: April 28, 2020Assignee: TAKEDA VACCINES, INC.Inventors: Jill Ann Livengood, Timothy Duane Powell
-
Patent number: 10525120Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.Type: GrantFiled: July 22, 2016Date of Patent: January 7, 2020Assignee: TAKEDA VACCINES, INC.Inventors: Dan Stinchcomb, Jorge E. Osorio, O'Neil Wiggan